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Sul'rll'nary 
Glucocorticoids are effective repressors of major histocompatibility complex (MHC) class II gene 
expression. The repression occurs in B cells, which constitutively express MHC class II, as well 
as in macrophages,  which only express MHC class II after the cells are treated with interferon 
%  For the MHC class II gene IA/~, this negative regulation has been linked to the X box DNA 
sequence, located with the IA3 promoter. The addition of the glucocorticoid receptor was shown 
to inhibit the DNA binding of the X box DNA binding protein to the X box. The DNA binding 
of two other DNA binding proteins that recognize elements within this promoter was unaffected 
by the addition of glucocorticoid receptor. It is likely that the repression of IA3 gene expression 
by glucocorticoids occurs because the X  box DNA binding protein is prevented from binding 
to the DNA and activating  transcription. 
T 
he MHC class II proteins play a central role in the devel- 
opment and maintenance of the immune system (1). They 
participate in the generation of the T  cell repertoire in the 
thymus and are required for antigen presentation to T lym- 
phocytes. Class II proteins are normally expressed on a limited 
number of cell types, which include B, thymic epithelial,  den- 
dritic,  and glial cells,  as well as activated macrophages  (2). 
The aberrant expression of class II proteins has been impli- 
cated in immune dysfunction. The lack of class II expression 
leads to a severe combined immunodeficiency (3), while the 
abnormal expression may be linked to the development of 
autoimmune diseases  (4, 5). Upstream of all MHC class II 
genes are at least three cis-acting elements that are essential 
for the transcriptional regulation of these genes (6). The ele- 
ments have been referred to as W,  X,  and Y,  and nuclear 
factors have been shown to bind each element  (6). 
Corticosteroids are important suppressors of the immune 
system, and one of the targets affected by corticosteroids is 
the expression of the MHC class II proteins, Corticosteroids 
have been found to repress MHC IA expression on B cells 
(8,  9) and the IFN-'y-induced expression of the MHC IA 
on macrophages (10, 11). The downregulation of MHC class 
II gene expression by corticosteroids appears to be at the level 
of transcription  (12,  13). 
In  the present  report,  we have examined  the  ability of 
glucocorticoids to negatively regulate the expression of the 
MHC class II gene IAB. Our results indicate that the mech- 
anism by which glucocorticoids inhibit IAB gene expression 
is by interfering with the DNA binding of the X box DNA 
binding protein. 
Materials  and Methods 
CeRs.  In these studies, the cell lines used included: A20-2J 
(mouse B lymphocyte), EL4 (mouse T lymphocyte),  and WR19 
M.1 (mouse macrophage).  Mouse bone marrow-derived  macro- 
phages (BMM) were produced in vitro using L cell-conditioned 
medium as described (14). After 6 d in culture, BMM were washed 
and incubated in the absence of L cell-conditioned  medium  for 
4 d. For IFN stimulation studies, 300 international reference units 
(IRU)/ml of murine IFN-'g (a gift from Genentech,  Inc., South 
San Francisco, CA) was added to the medium for 24 h. Under these 
conditions, IFN-3/induces  the expression of mRNA for IA~ and 
IA surface expression (15). The treatment of cells with dexametha- 
sone (Sigma Chemical Co., St. Louis, MO) (10 -6 M) was for 24 
or 48 h depending on the assay. RU 486 was a generous gift from 
Roussel Uclaf (RomanviUe, France). The RU 486 was dissolved 
in DMSO and used at a concentration  of 10 -6 M). Cells were 
treated with RU 486 for 24 h. 
Nuclear Extract Preparation.  Nuclear extracts were prepared as 
described previously (16). In brief, cells were lysed in a homogenizer 
(Dounce).  The crude nuclei were extracted at 4~  with a buffer 
containing  0.4 M NaCI for 30 rain with continuous stirring fol- 
lowed by centrifugation  at 10  s g for 1 h. The supernatant was di- 
alyzed, and extracts were cleared by centrifugation  at 104 g for 10 
rain. The supernatant  (protein concentration  of 1-5 mg/ml) was 
frozen in aliquots and stored at  -70~ 
RNA  Protection Assay.  The RNA protection  assay was per- 
formed as described (14, 15). For the analysis of IAB gene expres- 
sion, a 1.5-kb SacI-HindlII  fragment containing  the 81 exon of 
the IA~? gene was subcloned into the vector, pGEM1 (Promega 
Biotec, Madison, WI). In the RNA protection  assay, this 1.5-kb 
probe protected a fragment of 273 bases. Samples were electrophoret- 
ically separated on a 6% polyacrylamide-urea gel. As a control, 
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1.6-kb SacI fragment containing this gene was subdoned into the 
vector, pGEM1. This probe was made from the genomic clone 
RPL32-4A, kindly provided by Dr. R. P. Perry (Fox Chase Cancer 
Center, Philadelphia, PA) (17). The L32-4A plasmid was linear- 
ized at an AvalI site within the coding region giving a 0.7-kb probe 
in the ILNA transcription system. This probe protected a 410-base 
fragment in the RNA protection assay. 
Transfection Assays.  A20-2J (mouse B lymphocytes) cells were 
transfected in suspension  in 1 ml using the DEAE-dextran method 
(18). 15/~g of the experimental DNA and 3 #g of the plasmid, 
pCHl10, a B-galactosidase  expression  vector used to measure trans- 
fection efficiency  and 30/~g of DEAE~dextran, were added to each 
plate. In the cotransfection experiments with the glucocorticoid 
receptor or retinoic acid receptor, 2/~g of the indicated receptor 
was used. When dexamethasone was added in the cotransfection 
assay, it was added to the media after the DMSO shock treatment. 
Chloramphenicol acetyl transferase (CAT) assays  were performed 
using a standard protocol (19). Briefly,  cells  were isolated 48 h after 
the DNA was added and subjected to three freeze-thaw cycles in 
dry ice/ethanol and 37~  The extracts (10-60/zl standardized by 
fl-galactosidase activity) were incubated with [UC]chloramphen- 
icol and acetyl coenzyme A for 60 rain at 37~  heated 7 rain at 
60~  followed  by extraction with ethyl acetate. The samples were 
dried and resuspended  in 20/~1 of ethyl acetate for TIC. The quan- 
titation of acetylation was performed using a radioanalytic  imaging 
system (AMBIS, Inc., San Diego, CA). Each experiment was done 
at least three times, and the result of a representative experiment 
is shown in each figure. 
Plasmid Constructions.  The CAT reporter constructions were 
made using the KS+-SV2 CAT vector (20) in which the SV40 en- 
hancer region (SphI to PstI) was removed. This modified vector 
contains the SV40 promoter, but lacks the enhancer region. The 
different constructions, KS1-WXY (-124 to -26), KS1-X (-105 to 
-77), KS1-Y (-74 to -44), KS1-W (-137 to -108), and KS1 mutants 
(mutations in the W, X, or Y box as indicated in Fig. 5), con- 
taining different elements of the IA/~ promoter, were generated 
using specific  oligonucleotides  or by PCIL  using the plasmid 12.33.2, 
which contains the IAfl promoter (16). The DNA fragments were 
ligated directionally into XbaI-SmaI-digested KS1 vector. DNA 
fragments used for the gel electrophoresis  DNA binding assay  were 
generated by cloning. Double-stranded oligonudeotides were syn- 
thesized on a DNA synthesizer (380 A; Applied Biosystems  Inc., 
Foster City, CA) and cloned into the BamHI site of the vector, 
pGEM1. Plasmids  containing the genes for either the retinoic acid 
receptor (pECE RAR,8) or the glucocorticoid receptor (OB10-7) 
were obtained from Dr. M. Pfahl (La JoUa Cancer Research Foun- 
dation) (21, 22). The pECE vector contains the SV40 promoter 
and enhancer (23). In vitro transcription/translation of the gluco- 
corticoid receptor was performed as described  by the manufacturer 
(Promega Biotec). RNA was transcribed using T3 RNA poly- 
merase. The RNA template (2/~g) was added to a rabbit reticulo- 
cyte lysate (Promega Biotec) to generate in vitro [3SS]methionine- 
labeled protein. Protein production was confirmed by SDS-PAGE 
and autoradiography.  Gel electrophoresis  DNA binding assays  were 
performed directly with the in vitro translated product. The gels 
were dried and exposed to two sheets of Kodak XAR film to dis- 
tinguish the ssS label from the 3~p label. 
Gel Electrophoresis  DNA-binding Assay.  The plasmids containing 
the synthesized oligonudeotides were digested with HindIII, la- 
beled  by  filling in  the  ends with  c~[3zP]-labded dNTPs  and 
Klenow polymerase, and digested with EcotLI. A 70-bp fragment 
containing the desired protein binding site was then isolated from 
a 6% polyacrylamide gel. For gel electrophoresis DNA binding 
assays, binding was performed in a total volume of 20/xl in 12 mM 
Hepes (pH 7.9), 60 mM KC1, 5 mM MgCI~, 0.12 mM EDTA, 
0.3 mM PMSF, 0.3 mM DTT, 10,000 cpm of ~2P-labded DNA 
(0.1 ng),  2 ~g of poly(dI-dC), 12% glycerol, and the indicated 
amounts of nuclear extract. Binding was allowed to proceed for 
30 rain at 20~  (16). Samples  were then applied to a 6% polyacryl- 
amide gel (acrylamide/bisacrylamide,  30:1), 0.25 x TBE (lx TBE 
=  89 mM Tris, 89 mM boric acid, 2 mM EDTA) containing 5% 
glycerol, and electrophoresis was carried out for 1 h at 4~  at 250 
V (10 V/cm). After electrophoresis, the gels were dried and ex- 
posed to X-ray film (XAR5;  Kodak). 
Results 
The effect of dexamethasone treatment on the expression 
of the MHC class II gene IA~ was tested using various cell 
lines and normal bone marrow macrophages. The steady-state 
level of IA~ RNA isolated from these cells was measured 
using an RNA protection assay (Fig.  1).  A  probe for the 
ribosomal protein gene L32, whose RNA level does not 
change after treating the cells with IFN-3, or dexamethasone, 
was included as a control for each cell type. The B cell A20- 
2J constitutively expresses IAB mRNA, which resulted in 
a fragment of 273 bases being protected in the RNA protec- 
tion assay. The quantity of this protected fragment did not 
change significantly  when the cells were treated with IFN-y 
for 24 h before the RNA was isolated. When dexametha- 
sone was added for 24 h before the isolation of RNA, how- 
ever, the level of IAB mRNA was reduced considerably.  In 
bone marrow macrophages or the macrophage-like cell line 
WR19 M.1, both of which do not express  MHC class II 
genes unless treated with IFN-% a background level of IAB 
mRNA was observed. After the cells were treated with IFN-y 
for 24 h, the level of the IA~/mRNA increased  '~25-fold. 
When RNA was assayed from cells treated with both IFN-y 
and dexamethasone, no increase in the level of IAB mRNA 
above the background level was observed.  The T  cell line 
in EL4 does not normally express MHC class II mRNA and, 
therefore, the level of IAB mRNA is at a background level 
as measured by the RNA protection assay. The treatment 
of these cells with either IFN-'y or dexamethasone for 24 h 
did not have any significant effect on the level of IAB mRNA. 
The results indicated that in those cells that express  IA~/ 
mRNA, either constitutively as in B cells or after IFN-3' treat- 
ment as in macrophages, dexamethasone treatment lowered 
the level of IAB mRNA. 
To examine the basis for the repression  of IA~ expression 
by dexamethasone, we tested the possibility that transcrip- 
tion from the IA~ promoter may be affected by dexametha- 
sone treatment. Using the IAfl promoter linked to the CAT 
gene, we observed a low CAT activity when this construc- 
tion was transfected into the B cell line, A20-2J.  Because 
we were interested in the cell type-specific enhancing activity 
of the IA~/promoter, we linked a 124-bp  fragment of the 
IAB promoter containing the W, X, and Y boxes to the SV40 
promoter (Fig. 2), which then gave us a better signal in the 
CAT assay. This type of construction has been used by others 
to obtain more efficient expression  of other MHC class II 
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dexamethasone. Cells were incubated  for 24 h with 
IFN-7 (300  IRU/ml) and/or  dexamethasone  (10 -6 M) 
as indicated, total RNA was isolated, and 20/~g was 
analyzed  using an RNA protection  assay, as described 
in Materials and Methods. 
genes, including the IEo~ and IAcx genes (24-26). In addi- 
tion, previous published work has demonstrated that neither 
the SV40 enhancer nor promoter are influenced by glucocor- 
ticoids (27). Each CAT construction was cotransfected with 
the ~-galactosidase expression plasmid, pCH110, into the B 
cell line, A20-2J. All CAT values were then normalized to 
the level of B-galactosidase expression to correct for any differ- 
ences in transfection effidency. The cot,  structions containing 
the individual W, X, and Y sequences or the IA/5 promoter, 
each gave a higher level of CAT activity than the vector alone. 
The KS1 vector gave a level of CAT activity of <1%, while 
KS1 containing the W, X, and Y boxes gave a CAT activity 
of 18.5%  (Fig.  2). When a mutation of either the W, X, 
or Y box was made in the context of all three boxes, CAT 
activity was lowered to 10.5% for the W  box mutant, and 
2.0 and 7.0%  for the X  and Y  box mutants,  respectively. 
Each mutation was designed to disrupt the binding of a nu- 
clear factor to the respective box as measured by a gel dec- 
trophoresis DNA binding assay (data not shown).  For the 
constructions containing individual W,  X, or Y  dements, 
the CAT activities were 4.2,  10.3,  and 6.5%,  respectively. 
The addition  of dexamethasone to  the  transfected cells 
resulted in a decrease in CAT activity in ceils transfected with 
the KS1 constructions containing the X box sequence either 
alone or together with the W  and Y boxes. In cells trans- 
fected with the KS1-WXY construction, dexamethasone treat- 
ment resulted in a decreased CAT activity from 18.5 to 3.2%. 
Dexamethasone treatment also resulted in a decreased CAT 
activity from 10.5 to 3.6% in ceils transfected with the CAT 
construction, KSl-mutant W, in which the W  box has been 
mutated. When the Y box was mutated (KSl-mutant Y), 
CAT activity dropped from 7.0 to 3.2% when dexametha- 
sone was added to the ceils.  The KSl-mutant X  construct 
resulted in a CAT activity of only 2.0%, making it difficult 
to interpret the CAT activity (1.5%) when dexamethasone 
was also included. Dexamethasone had no effect on the CAT 
activity from cells transfected with the KS1-W or KS1-Y con- 
structions, but lowered the CAT activity from 10.3 to 2.8% 
in ceils transfected with the KS1-X construction. As a con- 
trol, transfected cells were also treated with retinoic acid, which 
did not adversely affect the level of CAT activity compared 
to the control for any of the constructions tested. Thus, the 
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Figure 2.  Repression  of IAB promoter expression  by 
ghcocorticoids.  A reporter  plasmid (15 #g) (top) containing 
fragments of the lAB promoter (WXY -124 to -26; W 
-137 to -108; X -105 to -77; or Y -74 to -44) was trans- 
fected  into A20-2J cells, together  with the ~3-galactosidase 
expression  plasmid. After  the DMSO shock  the cells  were 
incubated in DME plus 5% FCS in the presence  or ab- 
sence of 10-  6 M dexamethasone  or 10-6 M retinoic  acid 
for 48 h. The amount of cell extract  used for CAT assays 
was normalized  according  to the level  of B-galactosidase 
expression. The CAT enzymatic  activity  was quantitated 
using an imaging system (AMBIS, Inc.). 
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affect the level of CAT activity from those constructions con- 
taining  the X  box sequence. 
To determine if the effect of dexamethasone on IA/3 ex- 
pression was mediated by the glucocorticoid receptor, we 
cotransfected a receptor expression plasmid  (OB10-7) into 
A20-2J cells together with the CAT constructions. No change 
in the level of CAT expression was observed when cells were 
cotransfected with the pECE vector alone (Fig. 3). In cells 
cotransfected with the glucocorticoid  receptor  expression 
plasmid, however, there was a diminution of CAT activity 
in those cells transfected with CAT constructions containing 
the X box sequence. The CAT activity dropped from 18.0 
to 4.2% for the KS1-WXY construction. When either the 
W  or Y box were mutated, CAT activity fell from 11.1 to 
4.2% for the W box mutant and 7.0 to 4.1% for the Y box 
mutant. The X  box mutant only gave a CAT activity of 
~2.0%,  so  when the glucocorticoid receptor expression 
plasmid was cotransfected,  the drop in CAT activity was 
negligible. When the construction KS1-X was tested, CAT 
activity went from 10.8% in the absence of glucocorticoid 
receptor to 2.5% when the glucocorticoid receptor construc- 
tion was cotransfected. In contrast,  there was no reduction 
in CAT activity when the glucocorticoid receptor construc- 
tion was cotransfected with the KS1-W or KS1-Y construc- 
tions.  Cotransfection  of a construction able to express the 
retinoic acid  receptor together with any of the IA/~ construc- 
tions had no effect on CAT activity. Thus, the glucocorti- 
cold receptor was able to repress CAT activity in only those 
constructions  containing the X box sequence. 
Additional support for the involvement of the glucocorti- 
cold receptor in the repression of IA/3 expression was ob- 
tained by using the glucocorticoid receptor antagonist  RU 
486. The binding of RU 486 by the receptor results in an 
inactive receptor in most cases. We found that when RU 486 
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The glucocorticoid receptor mediates the repression of IA~  Figure 3. 
expression.  A20-2J cells were transfected  with 15/zg of the KS1-CAT 
plasmid containing different elements  of the IAB promoter as described 
in Fig. 2, together with 2/zg of the pECE vector (m), the glucocorticoid 
receptor expression plasmid (g~), or the retinoic acid receptor expression 
plasmid ([-]). CAT enzymatic activity was quantitated using an imaging 
system (AMBIS, Inc.). 
was added together with dexamethasone to cells transfected 
with the KS1-WXY construction, the repressive  effect  of  dexa- 
methasone was blocked (Fig. 4). Cells treated with both RU 
486 and dexamethasone had a level of CAT activity (16.0%) 
that was comparable to the control cells (16.3%).  In cells 
treated with dexamethasone alone, the CAT activity was low- 
ered to 4.6%. RU 486 by itself  had no affect on CAT activity 
when compared to the control. 
The blocking effect of RU 486 was also observed when 
RU 486 was added to cells cotransfected with a glucocorti- 
cold receptor expression construct (Fig. 4). In this experi- 
ment, the presence of the glucocorticoid  receptor reduced 
CAT activity from 16.3 to 3.8%. When RU 486 was added, 
the repression by the glucocorticoid receptor was blocked and 
CAT activity was 15.8%.  The addition  of dexamethasone 
to cells cotransfected with KS1-WXY and the glucocorti- 
cold receptor expression construct resulted in a CAT activity 
of 1.8%. This repression was completely reversed by the ad- 
dition of RU 486. These results emphasize that it is the glu- 
cocorticoid receptor that causes the repression of CAT ac- 
tivity in our assays and that this activity can be blocked by 
the drug RU 486. 
Recently, it has been demonstrated that the transcriptional 
interference between c-Jun and the glucocorticoid  receptor 
is due to a mutual inhibition of DNA binding due to the 
direct protein-protein  interaction between c-Jun, c-Fos, and 
the glucocorticoid receptor (27-31). To investigate if a similar 
mechanism could account for the transcriptional  repression 
of the IAB gene by the glucocorticoid  receptor, we tested 
the possibility that the glucocorticoid receptor may inhibit 
the interaction between a DNA binding protein and a DNA 
sequence within the IA~ promoter.  Using footprinting and 
competition assays, we showed previously that specific nu- 
clear factors bind to the Y box (16, 32), the X box (33), and 
the W box (Celada, A., and R. Maki, manuscript submitted 
for publication) of the IAB gene. Using nuclear extracts pre- 
pared from the B cell line A20-2J and cloned oligonudeo- 
tide probes covering the W, X, and Y boxes, a gel electropho- 
resis DNA binding assay  was performed (Fig. 5). Each probe 
Con(~AJ otle 
Cctrenstectlen 
pECE  G I  ~  :-;  :;-  --_-_-4  t I |  kl  recoplor 
Control 
Dexamethesono 
HU  486 
Dexemethesone  +  RU  486 
Percent  acetylatlen 
Figure 4.  Repression of lAB by the glucocorticoid receptor is blocked 
by the drug RU 486.  A20-2J cells were transfected  with 15 t~g of the 
KS1-WXY construction and cotransfected with 2/~g of pECE or an ex- 
pression construct containing the glucocorticoid receptor. Cells were treated 
with dexamethasone, RU 486, or a combination of both. CAT enzymatic 
activity was quantitated using an imaging system (AMBIS,  Inc.). 
694  Transcriptional  Repression  by Glucocorticoids was able to form a specific  complex with protein,  which ap- 
peared as a slower migrating band in the assay. The addition 
of cold double-stranded  oligonucleotide  competed for the 
binding of nuclear factor for the respective labded oligonu- 
cleotide, while oligonudeotides containing mutations within 
the W, X, or Y boxes were not able to compete for binding. 
The addition of  in vitro transcribed and translated glucocor- 
ticoid receptor had no effect on the DNA-protein complex 
seen using either the W or Y box probes (Fig. 5, A and C). 
No retarded complex, however, was seen when glucocorti- 
coid receptor was added to the reaction mix containing the 
X box probe (Fig. 5, B). The glucocorticoid receptor alone 
did not generate a retarded complex with either the W, X, 
or Y box probes, indicating that the glucocorticoid receptor 
was not binding directly to the DNA. Furthermore, no change 
in binding was seen when the retinoic acid receptor was added 
to the assay (Fig. 5). 
These results demonstrate that the glucocorticoid receptor 
inhibits  the binding of a nuclear factor present in B cells to 
the X box sequence. The results also provide a reasonable 
explanation  for the repression of IAfl expression seen in B 
cells treated with dexamethasone. 
Figure 5.  The glucocorticoid  receptor inhibits the binding of the X 
box binding protein.  Nuclear extracts from B lymphocytes (A20--2J cell 
line) were used for gel retardation assays with probes for W  (A), X (B), 
or Y (C) boxes in the presence or absence of in vitro transcribed/trans- 
lated ghcocorticoid receptor or the retinoic acid receptor. The relative 
concentration of protein for glucocorticoid or retinoic acid receptor was 
measured taking into account the amount of radiolabeled methionine in- 
corporated during the in vitro translation,  and was quantitated  using an 
imaging system (AMBIS, Inc.). The sequence of the oligonucleotide and 
respective mutant is given below each panel. 
Discussion 
It has been well established that corticosteroids cause a loss 
of MHC class II proteins on B cells and repress the cell sur- 
face expression of these proteins  on IFN-'y-treated macro- 
phages (8, 9, 11, 34). For the mouse MHC class II protein 
IA, this loss of cell surface expression can be linked to a re- 
duced level of mature RNA for both IAc~ (12, 13) and IAfl 
(Fig. 1). The mechanism leading to this lowering of RNA 
levels for IAfl appears to result from the inhibition of DNA 
binding of the X box DNA binding protein by the gluco- 
corticoid receptor. In a gel electrophoresis  DNA binding assay, 
the addition of  glucocorticoid  receptor inhibited the binding 
of a nuclear factor to the X box sequence, but did not inter- 
fere with the binding of nuclear factors to the W  or Y box 
sequences. 
The glucocorticoid receptor is a member of a superfamily 
of  intracellular receptors that act as modulators of gene tran- 
scription (35). These receptors become activated by binding 
steroids or related hormones (36, 37).  The glucocorticoid 
receptor was first shown to be a transcriptional activator that 
binds  directly to  a c/s-acting element, the glucocorticoid 
receptor response element. More recently, the glucocorticoid 
receptor has also been shown to act as a repressor. A number 
of  models have  been proposed for the mechanism of  this repres- 
sion. In the case of the genes for pro-opimelanocortin (38), 
prolactin (39), and chorionic gonadotropin c~ subunit (40, 41), 
the repression of transcription  appears to be mediated by the 
binding of  the glucocorticoid receptor to regulatory sequences, 
called negative glucocorticoid response elements.  The oc- 
cupancy of these sequences  by glucocorticoid receptor appears 
to prevent the binding of activating  factors to the DNA. 
Another example of  corticosteroid-induced gene repression 
involves the collagenase  gene family (42, 43). One of  the major 
regulatory elements within the promoters of these genes is 
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the AP-1  site is a protein complex composed of the c-Jun 
and c-Fos proteins.  It appears that the glucocorticoid receptor 
inhibits the expression of the coUagenase genes by binding 
to the c-Jun/c-Fos complex and preventing it from binding 
to the AP-1  recognition site on the DNA (27-31,  44). 
The inhibition of IAB gene expression by the glucocorti- 
coid receptor does not seem to be mediated by competition 
between the glucocorticoid receptor and the X box binding 
factor for binding to the DNA. This conclusion was reached 
based on the fndings that first, there is no consensus binding 
site for the glucocorticoid receptor in the X box sequence, 
and second, we did not see any retarded band in the gel elec- 
trophoresis DNA binding  assay when the glucocorticoid 
receptor was mixed with the labeled X box-containing DNA 
fragment. A  more likely possibility is that the glucocorti- 
coid receptor is interacting directly with the X box binding 
protein preventing the X box binding protein from binding 
to the DNA.  Recently, c-Fos has been shown to associate 
with hXBP-1, an X  box DNA binding protein that binds 
to the X box of the HLA-DRA and HLA-DP MHC genes 
(45, 46). One possible model for the repression of MHC class 
II gene expression would involve the binding of the gluco- 
corticoid receptor to the c-Fos protein, leading to an inhibi- 
tion of MHC class II transcription. It is unclear if c-Fos is 
necessary for the expression of the mouse MHC class II gene, 
IA~.  Experiments are in progress to test this possibility. 
The retinoic acid receptor has also been shown to inhibit 
AP-l-regulated transcription (47-49). As with the glucocor- 
ticoid receptor, the retinoic acid receptor interacts directly 
with the c-Jun/c-Fos complex in vitro (49). Since expression 
of the retinoic acid receptor in our cotransfection experiments 
had no effect on the expression of the lAB gene, c-Jun or 
c-Fos may not be involved in the expression of IAg/. 
The inhibitory effect of the glucocorticoid receptor on 
MHC class II gene expression may in part explain the clin- 
ical effects of glucocorticoids on the immune system. Mac- 
rophages play a key role in inflammatory processes  and re- 
quire the expression of class II molecules on the cell surface 
in order to present antigens to T cells (50).  In humans, glu- 
cocorticoid treatment is an established method for treating 
autoimmune diseases, and part of the effect could be related 
to the inhibition of class II expression. Murine models of 
autoimmune diseases in which animals were treated with anti- 
IA mAbs resulted in an increased survival rate from 10 to 
>90%  (51). 
Class II antigens are not only expressed on the cell surface 
of immunoreactive cells; other cell types, such as endothelial 
cells, fibroblasts,  and epithelial cells, can express class II an- 
tigens (1, 2). Moreover, the induction of class II antigens on 
these nonimmunoreactive cells plays an essential role in the 
augmentation of the immune response during autoimmune 
disease and graft rejection (52,  53).  The inhibition of class 
II antigen expression on renal tubular cells has been associated 
with the absence of graft rejection in rat renal allografts de- 
spite the presence of activated T cells within the graft (54). 
Finally, steroid therapy has been shown to reduce class II ex- 
pression on diseased tissues  (54,  55). 
Although, at present, we do not know the precise mecha- 
nism of glucocorticoid receptor interaction with the X box 
binding protein, these results may help in the design of new 
therapeutic approaches for the treatment of immunological 
diseases. 
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